Physician

Mohammad Alhaji, MD

According to 2025 Medicare claims, Mohammad Alhaji, MD (NPI: 1053627570) practices nephrology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is ALHAJI CONSULTANT PLLC (NPI: 1326586959; TIN: 81-4864680) and primary practice location at 48192-4668. Alhaji is affiliated with the CCA ACO LLC (ACO ID: A2198), McAuley Health Partners ACO, LLC (ACO ID: A4588), Mosaic ACO (ACO ID: A5033), and VillageMD New Hampshire ACO, LLC (ACO ID: D0106), participating under both the MSSP and REACH models.

Alhaji's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 635 traditional Medicare patients, billed 5,622 HCPCS/CPT codes, and received $474,577 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,806 prescription claims across 307 beneficiaries totaling $408,684 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2018 DME data shows 46 claims. Open Payments data shows 7 records totaling $1,733. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $50,107 to $474,577. Similarly, Part D prescription costs have moved sharply higher in recent years, from $6,623 to $408,684. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	404	572	$50,107
2016	408	829	$70,626
2017	647	1,776	$138,949
2018	635	4,048	$340,628
2019	540	4,473	$383,230
2020	682	5,875	$480,503
2021	706	5,129	$437,213
2022	698	5,421	$464,712
2023	779	6,100	$538,868
2024	635	5,622	$474,577

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	42	141	$6,623
2016	34	147	$15,063
2017	111	345	$12,516
2018	147	518	$42,491
2019	116	417	$38,256
2020	210	809	$61,521
2021	293	1,144	$70,588
2022	320	1,337	$182,626
2023	351	1,781	$353,626
2024	307	1,806	$408,684

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	24	$827
2018	N/R	46	$1,318
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	405	563	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	125	210	$94
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	352	1,619	$94
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	369	1,912	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	83	172	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	175	9,690	$176,149
Jardiance	Empagliflozin	101	6,469	$122,806
Kerendia	Finerenone	16	1,080	$21,766
Myrbetriq	Mirabegron	15	660	$9,788
Calcitriol	Calcitriol	320	20,442	$8,441

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$1,733	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammad Alhaji, MD?

Tedicare shows public-source Medicare data for Mohammad Alhaji, MD (NPI 1053627570), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad Alhaji, MD have ACO affiliation data?

Mohammad Alhaji, MD is shown with ACO affiliation data for CCA ACO LLC (MSSP, ACO ID A2198), McAuley Health Partners ACO, LLC (MSSP, ACO ID A4588), Mosaic ACO (MSSP, ACO ID A5033), and VillageMD New Hampshire ACO, LLC (REACH, ACO ID D0106).

What billing organization is linked to Mohammad Alhaji, MD?

Mohammad Alhaji, MD is linked to ALHAJI CONSULTANT PLLC (billing NPI 1326586959) in the available physician profile data.

Does Mohammad Alhaji, MD have Open Payments data?

Mohammad Alhaji, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.